PUBLISHER: The Business Research Company | PRODUCT CODE: 1855814
 
				PUBLISHER: The Business Research Company | PRODUCT CODE: 1855814
Cardiogenomics testing panels are genetic tests that examine multiple genes to determine inherited risks for cardiovascular diseases, including cardiomyopathies, arrhythmias, and familial hypercholesterolemia. They support early diagnosis, personalized treatment, and assessment of family risk.
The primary product types of cardiogenomics testing panels are single-gene panels, multi-gene panels, and whole exome sequencing panels. Single-gene panels test a specific gene to detect mutations or variants linked to a particular inherited condition or disease. The technologies employed include next-generation sequencing, PCR-based testing, microarrays, and others. These panels are applied in areas such as inherited cardiovascular diseases, arrhythmias, cardiomyopathies, congenital heart diseases, and others, and are used by hospitals and clinics, diagnostic laboratories, academic and research institutions, and other end users.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.
The cardiogenomics testing panels market research report is one of a series of new reports from The Business Research Company that provides cardiogenomics testing panels market statistics, including cardiogenomics testing panels industry global market size, regional shares, competitors with a cardiogenomics testing panels market share, detailed cardiogenomics testing panels market segments, market trends and opportunities, and any further data you may need to thrive in the cardiogenomics testing panels industry. This cardiogenomics testing panels market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cardiogenomics testing panels market size has grown rapidly in recent years. It will grow from $1.38 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to expanding reimbursement policies for genetic tests, an increasing number of genetic counseling services, greater focus on early diagnosis and prevention, rising public awareness initiatives, and wider adoption of telemedicine and remote diagnostics.
The cardiogenomics testing panels market size is expected to see rapid growth in the next few years. It will grow to $2.48 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to the increasing prevalence of cardiovascular diseases, growing awareness of genetic predispositions, higher demand for personalized medicine, greater availability of next-generation sequencing, and rising healthcare investments in genomics. Key trends in the forecast period include advancements in next-generation sequencing, integration of artificial intelligence for data analysis, development of multi-gene panels, progress in microarray technology, and incorporation of genomic data with electronic health records.
The rising prevalence of inherited cardiovascular diseases is expected to drive growth in the cardiogenomics testing panels market. Inherited cardiovascular diseases (ICDs) include heart and blood vessel disorders passed down genetically from parents to offspring. Advances in genetic testing and diagnostics have contributed to an increase in diagnosed cases by enabling more precise detection of previously unidentified conditions. Cardiogenomics testing panels assist in inherited cardiovascular diseases by analyzing genetic mutations responsible for hereditary heart disorders, facilitating early diagnosis, risk evaluation, and personalized treatment plans. For example, in February 2025, the Joint Strategic Needs Assessment, a UK community health center, reported that Blackpool recorded 185 cardiovascular disease deaths in 2023 compared to 178 in 2022. This growing prevalence is fueling expansion in the cardiogenomics testing panels market.
Increasing healthcare expenditure is anticipated to boost the cardiogenomics testing panels market. Healthcare expenditure encompasses the total resources spent by governments, private entities, and individuals on delivering, maintaining, and improving health services and medical care. The rise in spending is driven by the growing burden of chronic diseases that require long-term management, ongoing monitoring, and specialized interventions. These expenditures support cardiogenomics testing panels by funding advanced genetic analyses that enable early detection and prevention of inherited cardiovascular conditions, improving patient outcomes and lowering long-term costs. For instance, in December 2023, the Centers for Medicare & Medicaid Services, a US federal agency, reported that healthcare spending in the US increased by 4.1% in 2022, reaching $4.5 trillion, up from 3.2% growth in 2021. This trend contributes to market growth in cardiogenomics testing panels.
In March 2022, LetsGetChecked, a US healthcare solutions provider, acquired Veritas Genetics Inc. and Veritas Intercontinental S.L. for an undisclosed amount. This acquisition aims to utilize whole genome sequencing to offer a comprehensive personalized healthcare lifecycle by integrating detailed genetic data into scalable diagnostic and virtual care platforms, delivering actionable recommendations and lifestyle guidance from clinical experts. Veritas Genetics Inc. and Intercontinental S.L. are US-based biotechnology firms providing cardiogenomics testing panels.
Major players in the cardiogenomics testing panels market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Illumina Inc., Actia Group, Invitae Corporation, Fulgent Genetics Inc., GeneDx Inc., Ambry Genetics Corporation, Helix OpCo Inc., Centogene Gmbh, Blueprint Genetics Inc., Strand Life Sciences Pvt. Ltd., Genes2Me Pvt. Ltd., BioAro Inc., GENinCode Plc, Igenomix S.L., Asper Biotech Ltd.
North America was the largest region in the cardiogenomics testing panels market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiogenomics testing panels report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cardiogenomics testing panels market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cardiogenomics testing panels market consists of revenues earned by entities by providing services such as genetic risk assessment, early diagnosis, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiogenomics testing panels market also includes sales of comprehensive cardiomyopathy panels, cardiac arrhythmia panels, and direct-to-consumer genomic profiles. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cardiogenomics Testing Panels Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cardiogenomics testing panels market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cardiogenomics testing panels ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiogenomics testing panels market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
 
                 
                 
                